Triple Drug Combo for Advanced Breast Cancer
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you are currently on warfarin or other coumarin derivatives, or if you have used strong CYP3A4 or CYP2C8 inhibitors or inducers recently. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the triple drug combo for advanced breast cancer?
The combination of HER2-targeted drugs like trastuzumab (Herceptin) and tucatinib (Tukysa) has shown to significantly improve outcomes for patients with HER2-positive advanced breast cancer. Additionally, eribulin has been proven to extend overall survival in patients with advanced breast cancer who have undergone multiple prior treatments.12345
Is the triple drug combo for advanced breast cancer safe?
The combination of eribulin and trastuzumab has been shown to be generally safe and well-tolerated in patients with advanced HER2-positive breast cancer. Common side effects include neutropenia (low white blood cell count), which is manageable, and no severe heart issues were observed. However, regular monitoring of heart function is recommended.678910
What makes the triple drug combo of Eribulin, Trastuzumab, and Tucatinib unique for advanced breast cancer?
What is the purpose of this trial?
The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.
Research Team
Hank Kaplan, MD
Principal Investigator
henry.kaplan@swedish.org
Eligibility Criteria
This trial is for adults with HER2+ breast cancer that's advanced and can't be surgically removed. Participants must have had prior treatments including trastuzumab and a taxane, but not necessarily tucatinib. They should be in relatively good health otherwise, able to follow the study plan, and women of childbearing age must test negative for pregnancy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive tucatinib, trastuzumab, and eribulin in 21-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Eribulin
- Trastuzumab
- Tucatinib
Eribulin is already approved in European Union, United States, Japan, Canada for the following indications:
- Locally advanced or metastatic breast cancer
- Metastatic breast cancer
- Liposarcoma
- Breast cancer
- Soft tissue sarcoma
- Metastatic breast cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Criterium, Inc.
Lead Sponsor